Galderma has shared positive two-year data for its monoclonal antibody Nemluvio (nemolizumab) in moderate-to-severe atopic ...

Swiss skincare specialist Galderma has announced two-year data from a new interim analysis of a long-term extension study ...

Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the saf ...

Galderma (SIX: GALD) today announced two-year ... sustained and increased improvements in symptoms including itch and skin lesions with prolonged treatment up to two years.1 These data will ...

New interim two-year data from a long-term extension study of Nemluvioin atopic dermatitis reinforce its rapid onset of action and demonstrate its ...

ZUG, Switzerland, June 06, 2025--Galderma (SIX: GALD ... sustained and increased improvements in symptoms including itch and skin lesions with prolonged treatment up to two years.

Two trials from the OLYMPIA programme meanwhile showed that Galderma’s therapy was effective in reducing itch and skin lesions. Galderma’s CEO Flemming Ørnskov said: “As the first biologic ...

“Relentless itch makes life so difficult for the many people living ... were then re-randomized to a maintenance treatment phase for up to 48 weeks. Galderma (SIX: GALD) is the pure-play dermatology ...

More details on Galderma’s scientific presentations at RAD can be found ... headache, joint pain, hives (itchy red rash or wheals), and muscle aches Prurigo Nodularis: headache and skin rashes: atopic ...

Galderma (SIX: GALD) today announced two-year data from a new ... reinforcing its rapid onset of action and demonstrating sustained and increased improvements in symptoms including itch and skin ...